Inhibitor Therapeutics, Inc. (INTI)
| Market Cap | 7.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.45M |
| Shares Out | 172.57M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,500 |
| Average Volume | 6,796 |
| Open | 0.0370 |
| Previous Close | 0.0599 |
| Day's Range | 0.0370 - 0.0430 |
| 52-Week Range | 0.0338 - 0.0988 |
| Beta | -0.39 |
| RSI | 60.91 |
| Earnings Date | Nov 10, 2025 |
About Inhibitor Therapeutics
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. ... [Read more]
Financial Performance
Financial StatementsNews
Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Complement Inhibitors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight
The complement inhibitors market is gaining momentum due to the rising recognition of the complement system's role in driving rare and chronic diseases, such as paroxysmal nocturnal hemoglobinuria (PN...
Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan
TAMPA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) today provided an update on development efforts for its itraconazole formulation for the treatme...
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
Scientific Advisory Board tasked with critical review of Phase 2b trial results to assess clinical usefulness prior to submission of New Drug Application ("NDA") to FDA TAMPA, Fla. , Dec. 19, 2023 /PR...
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
A critical milestone completed on the mission path of commercializing Itraconazole in numerous oncology indications. TAMPA, Fla.